<![CDATA[Phase 3 MEVPRO-1 and MEVPRO-2 Trials Set to Evaluate EZH2 Inhibition Plus Enzalutamide in mCRPC]]>
After displaying early efficacy in a phase 1 trial (NCT03460977), the EZH2 inhibitor mevrometostat (PF-06821497) in combination with enzalutamide (Xtandi) will be examined in the phase 3 MEVPRO-1 (NCT06551324) and MEVPRO-2 (NCT06629779) trials for patients …